CN115105513A - Pharmaceutical composition for adjuvant therapy of cervical cancer - Google Patents
Pharmaceutical composition for adjuvant therapy of cervical cancer Download PDFInfo
- Publication number
- CN115105513A CN115105513A CN202210981517.8A CN202210981517A CN115105513A CN 115105513 A CN115105513 A CN 115105513A CN 202210981517 A CN202210981517 A CN 202210981517A CN 115105513 A CN115105513 A CN 115105513A
- Authority
- CN
- China
- Prior art keywords
- cervical cancer
- pharmaceutical composition
- cyperone
- alpha
- diosgenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010008342 Cervix carcinoma Diseases 0.000 title claims abstract description 32
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title claims abstract description 32
- 201000010881 cervical cancer Diseases 0.000 title claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 238000009098 adjuvant therapy Methods 0.000 title claims abstract description 19
- FBSFWRHWHYMIOG-UHFFFAOYSA-N methyl 3,4,5-trihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=C(O)C(O)=C1 FBSFWRHWHYMIOG-UHFFFAOYSA-N 0.000 claims abstract description 54
- KUFXJZXMWHNCEH-DOMZBBRYSA-N (4as,7r)-1,4a-dimethyl-7-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one Chemical compound C1CC(=O)C(C)=C2C[C@H](C(=C)C)CC[C@]21C KUFXJZXMWHNCEH-DOMZBBRYSA-N 0.000 claims abstract description 27
- KUFXJZXMWHNCEH-UHFFFAOYSA-N cyperone Natural products C1CC(=O)C(C)=C2CC(C(=C)C)CCC21C KUFXJZXMWHNCEH-UHFFFAOYSA-N 0.000 claims abstract description 27
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 claims abstract description 25
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 claims abstract description 25
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 claims abstract description 25
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 claims abstract description 24
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000007708 morin Nutrition 0.000 claims abstract description 24
- IBKQQKPQRYUGBJ-UHFFFAOYSA-N methyl gallate Natural products CC(=O)C1=CC(O)=C(O)C(O)=C1 IBKQQKPQRYUGBJ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- HDHRTQZSBFUBMJ-UHFFFAOYSA-N Artonin E Natural products O1C2=C3C=CC(C)(C)OC3=CC(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC(O)=C(O)C=C1O HDHRTQZSBFUBMJ-UHFFFAOYSA-N 0.000 claims description 2
- XFFOMNJIDRDDLQ-UHFFFAOYSA-N morusin Chemical compound O1C2=C3C=CC(C)(C)OC3=CC(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC=C(O)C=C1O XFFOMNJIDRDDLQ-UHFFFAOYSA-N 0.000 claims description 2
- WUBUWBUVAKMGCO-UHFFFAOYSA-N morusin Natural products CC(=CCC1=C(Cc2c3C=CC(C)(C)Oc3cc(O)c2C1=O)c4ccc(O)cc4O)C WUBUWBUVAKMGCO-UHFFFAOYSA-N 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009803 radical hysterectomy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the technical field of medicines, and in particular relates to a pharmaceutical composition for adjuvant therapy of cervical cancer, which comprises diosgenin, morin, methyl gallate and alpha-cyperone. Wherein the mass ratio of diosgenin, morin, methyl gallate and alpha-cyperone is as follows: 5:1-3:3-5: 2-3. The pharmaceutical composition provided by the invention can effectively inhibit the growth and reproduction of cervical cancer cells and simultaneously induce the rapid apoptosis of the cervical cancer cells.
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to a pharmaceutical composition for adjuvant therapy of cervical cancer.
Background
Cervical cancer is a malignant tumor that occurs in the cervix, accounts for more than half of the malignant tumors of the female reproductive system, and has the first mortality rate of female malignant tumors. The development of cervical cancer is a complex and slow process, and is closely related to the infection with Human Papilloma Virus (HPV).
At present, cervical cancer mainly adopts treatment modes such as operation treatment, external radiation radiotherapy, intracavity radiotherapy, auxiliary chemotherapy and the like. Generally, radical hysterectomy and pelvic lymph node cleaning are selected for early-stage cervical cancer, and the treatment effect is good; when the surgical indication is not met, radiation therapy can be adopted; however, the prognosis is relatively poor for advanced and recurrent cervical cancer. Despite advances in surgical and adjuvant therapies, development and recurrence of the disease continues to afflict women with cervical cancer, and finding effective treatments is critical, especially in middle-to-advanced and recurrent patients, where effective chemotherapy is important.
Disclosure of Invention
In order to solve the problems, the invention provides a pharmaceutical composition for adjuvant therapy of cervical cancer, which can obviously inhibit the proliferation of cervical cancer cells.
In order to achieve the purpose, the invention adopts the technical scheme that:
a pharmaceutical composition for adjuvant treatment of cervical cancer comprises diosgenin, morin, methyl gallate and alpha-cyperone.
Preferably, the mass ratio of diosgenin, morin, methyl gallate and alpha-cyperone is as follows: 5: 1-3:3-5: 2-3.
Preferably, the mass ratio of diosgenin, morin, methyl gallate and alpha-cyperone is as follows: 5: 3: 5: 3.
preferably, the mass ratio of diosgenin, morin, methyl gallate and alpha-cyperone is as follows: 5:2:4: 2.5.
preferably, the mass ratio of diosgenin, morin, methyl gallate and alpha-cyperone is as follows: 5: 1:3: 2.
preferably, the mass ratio of diosgenin, morin, methyl gallate and alpha-cyperone is as follows: 5: 3:3: 3.
as a further design of the scheme, the pharmaceutical composition for the adjuvant therapy of the cervical cancer also comprises pharmaceutically conventional auxiliary materials.
The pharmaceutical composition provided by the invention can effectively inhibit the growth and reproduction of cervical cancer cells and simultaneously induce the rapid apoptosis of the cervical cancer cells.
Detailed Description
The present invention will be described in detail with reference to specific examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention.
Example 1
A pharmaceutical composition for adjuvant treatment of cervical cancer comprises diosgenin, morin, methyl gallate and alpha-cyperone according to a mass ratio of 5: 1: 3: 2, and mixing the components.
Example 2
A pharmaceutical composition for adjuvant treatment of cervical cancer comprises diosgenin, morin, methyl gallate and alpha-cyperone according to a mass ratio of 5: 3: 5: 3, and mixing the components in a ratio of 3.
Example 3
A pharmaceutical composition for adjuvant treatment of cervical cancer comprises diosgenin, morin, methyl gallate and alpha-cyperone according to a mass ratio of 5:2: 4: 2.5 in proportion.
Example 4
A pharmaceutical composition for adjuvant treatment of cervical cancer comprises diosgenin, morin, methyl gallate and alpha-cyperone in a mass ratio of 5: 3:3, and mixing the components in a ratio of 3.
Test data:
the half inhibition concentration (IC50) of the sample on the growth of the tumor cells is calculated by using a LOGIT method and the apoptosis of the Hela cells is detected by using a flow cytometer by using human cervical carcinoma Hela cells as test materials so as to determine the inhibition of the growth of the tumor cells of the examples 1-4 and each single dose, wherein:
test group 1: diosgenin 0.5mg, morin 0.1 mg, gallic acid methyl ester 0.3 mg and alpha-cyperone 0.2 mg;
test group 2: diosgenin 0.5mg, morin 0.3 mg, methyl gallate 0.5mg and alpha-cyperone 0.3 mg;
test group 3: diosgenin 0.5mg, morin 0.2mg, methyl gallate 0.4 mg and alpha-cyperone 0.25 mg;
test group 4: diosgenin 0.5mg, morusin 0.3 mg, methyl gallate 0.3 mg and alpha-cyperone 0.3 mg;
control group 1: diosgenin 0.5 mg;
for group 2: mulberry leaf spicerin 0.1 mg
For group 3: 0.3 mg of morin;
control group 4: 0.2mg of morin;
control group 5: gallic acid methyl ester 0.3 mg;
control group 6: gallic acid methyl ester 0.4 mg;
control group 7: gallic acid methyl ester 0.5 mg;
control group 8: 0.2mg of alpha-cyperone;
control group 9: 0.3 mg of alpha-cyperone;
control group 10: 0.25 mg of alpha-cyperone;
blank control group: the method is characterized in that DMEM culture medium is added without adding human cervical carcinoma Hela cells.
As a result:
compared with single preparation, when diosgenin, morin, methyl gallate and alpha-cyperone are used together, half inhibitory concentration (IC50) can be obviously reduced, and IC50 is 17.63-18.31 mu g/ml.
Compared with each single preparation, when the diosgenin, the morin, the methyl gallate and the alpha-cyperone are used together, the apoptosis of cervical cancer cells can be remarkably promoted, and the apoptosis rate is remarkably increased along with the prolonging of the action time. The apoptosis rate after 72 hours of action can reach 45.37%.
In conclusion, the pharmaceutical composition provided by the invention can effectively inhibit the growth and reproduction of cervical cancer cells and simultaneously induce the rapid apoptosis of the cervical cancer cells.
The foregoing description of specific embodiments of the present invention has been presented. It is to be understood that the present invention is not limited to the specific embodiments described above, and that various changes and modifications may be made by one skilled in the art within the scope of the appended claims without departing from the spirit of the invention.
Claims (7)
1. A pharmaceutical composition for adjuvant therapy of cervical cancer is characterized in that: comprises diosgenin, morusin, methyl gallate and alpha-cyperone.
2. The pharmaceutical composition for the adjuvant treatment of cervical cancer according to claim 1, wherein: the mass ratio of diosgenin to morin to methyl gallate to alpha-cyperone is as follows: 5: 1-3:3-5: 2-3.
3. The pharmaceutical composition for adjuvant therapy of cervical cancer according to claim 2, wherein: the mass ratio of diosgenin to morin to methyl gallate to alpha-cyperone is as follows: 5: 3: 5: 3.
4. the pharmaceutical composition for the adjuvant treatment of cervical cancer according to claim 2, wherein: the mass ratio of diosgenin to morin to methyl gallate to alpha-cyperone is as follows: 5:2:4: 2.5.
5. the pharmaceutical composition for the adjuvant treatment of cervical cancer according to claim 2, wherein: the mass ratio of diosgenin to morin to methyl gallate to alpha-cyperone is as follows: 5: 1: 5: 3.
6. the pharmaceutical composition for adjuvant therapy of cervical cancer according to claim 2, wherein: the mass ratio of diosgenin to morin to methyl gallate to alpha-cyperone is as follows: 5: 3:3: 3.
7. the pharmaceutical composition for adjuvant treatment of cervical cancer according to claim 1, wherein: the method is characterized in that: also comprises pharmaceutic conventional auxiliary materials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210981517.8A CN115105513A (en) | 2022-08-16 | 2022-08-16 | Pharmaceutical composition for adjuvant therapy of cervical cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210981517.8A CN115105513A (en) | 2022-08-16 | 2022-08-16 | Pharmaceutical composition for adjuvant therapy of cervical cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115105513A true CN115105513A (en) | 2022-09-27 |
Family
ID=83335892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210981517.8A Pending CN115105513A (en) | 2022-08-16 | 2022-08-16 | Pharmaceutical composition for adjuvant therapy of cervical cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115105513A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114028381A (en) * | 2021-12-09 | 2022-02-11 | 黑龙江中医药大学 | Medicine for treating ovarian cancer and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506051A (en) * | 2002-12-10 | 2004-06-23 | 吉林天药科技股份有限公司 | Antitumor use of diosgenin |
| CN103027231A (en) * | 2013-01-01 | 2013-04-10 | 蒋常德 | Compound probiotics fermented Chinese herbal medicine active health care liquid and preparation method thereof |
| CN104800204A (en) * | 2014-01-27 | 2015-07-29 | 四川大学华西医院 | Anti-tumor application of morin |
| CN112773821A (en) * | 2021-01-13 | 2021-05-11 | 石河子大学 | Preparation method and application of gallnut polyphenol |
-
2022
- 2022-08-16 CN CN202210981517.8A patent/CN115105513A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506051A (en) * | 2002-12-10 | 2004-06-23 | 吉林天药科技股份有限公司 | Antitumor use of diosgenin |
| CN103027231A (en) * | 2013-01-01 | 2013-04-10 | 蒋常德 | Compound probiotics fermented Chinese herbal medicine active health care liquid and preparation method thereof |
| CN104800204A (en) * | 2014-01-27 | 2015-07-29 | 四川大学华西医院 | Anti-tumor application of morin |
| CN112773821A (en) * | 2021-01-13 | 2021-05-11 | 石河子大学 | Preparation method and application of gallnut polyphenol |
Non-Patent Citations (1)
| Title |
|---|
| 施树云;张宇平;周宏灏;黄可龙;: "管花蒲公英中抗肿瘤活性化合物的快速筛选研究" * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114028381A (en) * | 2021-12-09 | 2022-02-11 | 黑龙江中医药大学 | Medicine for treating ovarian cancer and application thereof |
| CN114028381B (en) * | 2021-12-09 | 2023-01-31 | 黑龙江中医药大学 | Medicine for treating ovarian cancer and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haddow et al. | Influence of synthetic oestrogens on advanced malignant disease | |
| CN115105513A (en) | Pharmaceutical composition for adjuvant therapy of cervical cancer | |
| Varga et al. | Effect of 17-alpha-hydroxyprogesterone 17-n-caproate on various pelvic malignancies | |
| CN114948938B (en) | Application of atractylenolide I in preparation of medicine for preventing and/or treating cervical cancer | |
| Chlebowski et al. | Long-term survival following levamisole or placebo adjuvant treatment of colorectal cancer: a Western Cancer Study Group Trial | |
| CN116570589A (en) | Application of compound Parimiferator in preparation of antitumor drugs | |
| US20230241081A1 (en) | Method for Treating Melanoma | |
| CN115645437A (en) | Application of fullerene preparation in preparation of medicine for treating intestinal cancer | |
| Smith et al. | Vindesine in the treatment of breast cancer | |
| CN113274394A (en) | Pharmaceutical composition for treating tyrosine kinase inhibitor drug-resistant non-small cell lung cancer | |
| Cohen et al. | Cancer and Hidradenitis Suppurativa | |
| CN118615268A (en) | Application of fingolimod in preparation of cancer treatment medicines | |
| CN110585429A (en) | Application of tyrosine kinase inhibitor combined with monoclonal antibody and taxol medicaments in treating tumor diseases | |
| CN113925850B (en) | Use of D-mannose in combination with PD-1 antibodies in the preparation of a medicament for the treatment of triple negative breast cancer | |
| CN117085135B (en) | Use of squalene epoxidase inhibitor in preparation of medicine for treating endometrial cancer | |
| CN116492321B (en) | Antitumor pharmaceutical composition and application thereof | |
| CN111494397B (en) | Application of ophiopogonin compounds in preparing medicines for preventing and treating tumors | |
| CN115137729B (en) | Small molecule medicine for preventing and/or treating CRC and application thereof | |
| CN110903246A (en) | Compound for treating thyroid cancer and composition and medical application thereof | |
| CN118119610A (en) | A pharmaceutical composition for treating cancer | |
| CN113855683A (en) | Medicinal composition of topotecan and 17 beta-estradiol and application thereof | |
| CN118178431A (en) | Application of glycolysis inhibitor in preparation of medicine for treating eyelid sebaceous gland cancer | |
| CN117159545A (en) | Application of pitchon in preparation of ovarian cancer treatment medicine | |
| CN117100730A (en) | Application of hydroxyurea in preparation of medicine for preventing or treating conjunctival melanoma | |
| CN117442611A (en) | Application of PREX-in1 in preparing tumor radiotherapy synergist or preparing medicine for treating colorectal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220927 |